CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Instagram Outage Disrupts Thousands of U.S. Users 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
REHOVOT, Israel and BRIDGEWATER, N.J., July 26, 2017 -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that it will report its financial results for the three and six months ended June 30, 2017, and will host a corporate update conference call and webcast at 8:30am Eastern Time on Wednesday, August 9, 2017.
| Conference Call & Webcast | |
| Wednesday, August 9, 2017 @ 8:30 am Eastern Time | |
| Toll Free: | 877-780-3381 |
| International: | 913-312-1403 |
| Conference ID: | 2390109 |
| Webcast: | http://public.viavid.com/index.php?id=125169 |
| Replays, Available through August 23rd: | |
| Toll-Free: | 844-512-2921 |
| International: | 412-317-6671 |
| Conference ID: | 2390109 |
About Foamix Pharmaceuticals Ltd.
Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy.
Our clinical stage product candidates include our novel minocycline foam FMX101 for the treatment of moderate-to-severe acne, FMX103 for the treatment of moderate-to-severe rosacea, FMX102 for the treatment of impetigo, and FDX104, our doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs.
In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare and others.
For more information, please visit www.foamixpharma.com.
Contact: Ilan Hadar, Country Manager & CFO Foamix Pharmaceuticals Ltd. +972-8-9316233 [email protected] US Investor Relations Michael Rice LifeSci Advisors, LLC 646-597-6979 [email protected]
